Skip to main content

Table 4 Laboratory and clinical parameters of the patients undergoing MTX or MTX plus infliximab therapy at baseline (first visit) and after six treatments (seventh visit)

From: Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor

  MTX (n = 8) MTX + infliximab (n = 15)
  first visit seventh visit first visit seventh visit
DAS 44 5.2 ± 0.4 4.4 ± 0.4* 5.8 ± 0.5 3.9 ± 0.5*
RF (IU) 210.1 ± 117.9 146.4 ± 80.4 396.2 ± 178.4 257.3 ± 142.8*
CRP (mg/dl) 0.8 ± 0.3 0.6 ± 0.2 1.8 ± 0.5 1.1 ± 0.3
ESR (mm/hour) 36.9 ± 5.4 31.9 ± 5.0 60.2 ± 8.1 44.2 ± 5.5*
SJC 19.6 ± 4.6 14.0 ± 3.0 21.9 ± 3.1 11.6 ± 2.4*
TJC 25.8 ± 4.9 16.0 ± 4.3* 27.0 ± 4.5 12.1 ± 3.4*
  1. Data are means ± standard error of the mean.
  2. * P < 0.05 between first and seventh visit.
  3. CRP = C-reactive protein; DAS = disease activity score; ESR = erythrocyte sedimentation rate; MTX = methotrexate; RF = rheumatoid factor; SJC = swollen joints count; TJC = tender joints count.